London · Delayed Price · Currency is GBP · Price in GBX Intercede Group Earnings Call Transcripts
Fiscal Year 2026
-
FY26 revenue slipped on delayed U.S. federal orders, which arrived after year-end; recurring revenue grew 11.4%. FY27 revenue guidance remains £21m, backed by a strong pipeline, continued R&D investment and partner-led expansion.
-
H1 revenue declined 3.9% nominally amid U.S. timing delays and lower professional services, but cash generation remained positive and debt-free. Management expects H2 normalization, sees recent order momentum, and is expanding toward subscription and enterprise credential management.
-
FY25 revenue was £17.7m after an exceptional prior-year U.S. order; normalized growth, recurring revenue and cash generation underpin a positive outlook. Product expansion and international demand support the double-digit organic growth target.
-
H1 revenue rose 22% to £8.54m and PBT increased 55% to £1.7m. Strong pipeline maturity supports confidence in the full-year forecast, while product launches and international opportunities broaden growth prospects.
-
FY24 revenue reached a record GBP 20m, with GBP 6m net profit and GBP 9.6m operating cash generation. A broader three-product portfolio, hybrid pricing and regulatory-driven demand underpin the ambition to double FY23 revenue.